Osaic Holdings’s Loncar China BioPharma ETF CHNA Stock Holding History

Osaic Holdings’s Portfolio CHNA Stock Details CHNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-830	Closed	-$31K	–	7678
2021 Q3	$31K	Sell	830 -92	-10%	-$3.75K	﹤0.01%	5466
2021 Q2	$44K	Buy	+922	New	+$39K	﹤0.01%	5144
2021 Q1	–	Sell	-719	Closed	-$23K	–	7005
2020 Q4	$23K	Buy	719 +35	+5%	+$1.07K	﹤0.01%	5081
2020 Q3	$21K	Buy	+684	New	+$21.6K	﹤0.01%	4892
2020 Q2	–	Sell	-500	Closed	-$11K	–	6406
2020 Q1	$11K	Buy	+500	New	+$12.4K	﹤0.01%	4968

Other funds holding CHNA

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BBPWM

Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return

Osaic Holdings's CHNA Position: Q4 2021 in Review

Osaic Holdings sold out of Loncar China BioPharma ETF (CHNA) in Q4 2021, closing a stake of 830 shares — an estimated $31K sold.

Osaic Holdings first reported a position in CHNA in Q1 2020 and held it in 5 quarters. The position peaked at $44K in Q2 2021. 4 funds tracked by Wall St. Rank hold CHNA as of Q4 2021.

Osaic Holdings reported no remaining Loncar China BioPharma ETF position as of Q4 2021 after selling out during the quarter.
Osaic Holdings sold 830 Loncar China BioPharma ETF shares in Q4 2021, an estimated $31K.
Osaic Holdings first reported a position in Loncar China BioPharma ETF in Q1 2020 and held it in 5 quarters.
Osaic Holdings's Loncar China BioPharma ETF position peaked at $44K in Q2 2021.
4 funds tracked by Wall St. Rank held Loncar China BioPharma ETF as of Q4 2021.

Based on Osaic Holdings's 13F filing for Q4 2021, filed 3 Feb 2022.